Abnormal Dendritic Cell-­poiesis in Patients With Lower-risk Myelodysplastic Syndromes

Ángela Sánchez1, Eduardo Anguita2, Alberto Chaparro2, Juan José Roldán-­Etchevery2, Alberto López-­García2, Carlos Ramos-­Acosta2, Raluca Oancea3, Diego Rodriguez-­Muñoz1, Susana Alemany1

Correspondence: Eduardo Anguita (e-mail: eduardo.anguita@salud.madrid.org)

Myelodysplastic syndromes (MDS) are clonal hematopoietic stem/progenitor cell disorders associated with ineffective hematopoiesis and peripheral blood cytopenia(s). Mounting evidence suggests that immune system regulation plays an important role in MDS pathogenesis and progression. The Revised International Prognostic Scoring System (IPSS-­R) divided MDS patients in four risk groups, in which, for simplicity’s sake, very low, low, and intermediate risk groups can be united into one lower-risk MDS group, as higher-risk MDSs are closer to acute myeloid leukemia.

The dendritic cell (DC) system forms an essential interface in innate immunity and plays a fundamental role in sensing pathogens and activating adaptive immunity. Circulating DCs are divided in three major subtypes: conventional dendritic cells 1 (cDC1s), plasmacytoid dendritic cells (pDCs), and conventional dendritic cells 2 (cDC2s), each specialized in responding to particular pathogens and interacting with specific subsets of T cells (Supplementary Table 1, http://links.lww.com/HS/A61).

As MDS progresses, the number of all three types of circulating DCs in lower-risk MDS was lower in MDS patients respect to the controls (Supplementary Table 3, http://links.lww.com/HS/A61). To note, the 3 different types of circulating DCs showed similar forward scatter area (FSC-­A) and side scatter area (SSC-­A) values, both in controls and MDSs (data not shown). The reduction in all 3 circulating DC types in MDS patients yielded a combined concentration of 2954 ± 568 DCs/ml, which represent the 0.063 ± 0.009% of the PBLs. In the control group, the total circulating CD123+HLA-­DR+CD14/CD16dim/neg and CD33+HLA-­DR+CD14/CD16dim/neg, respectively. To further explore these data, the three circulating DCs types, cDC1s, pDCs, and cDC2s were analyzed in 19 lower-risk MDS patients, and in 32 age-­ and sex-matched controls by flow cytometry, using a strategy in which all three DC types can be distinguished (Fig. 1A and Supplementary Methods, http://links.lww.com/HS/A61).

Patients with MDS showed a significant decrease in circulating cDC1s, pDCs, and cDC2s compared to controls, with a 70% diminution in the absolute number of each of the three types of DCs (Fig. 1B). The percentages of cDC1s, pDCs, and cDC2s within the PBLs of the patients decreased with respect to the controls by a 69.3% (p = 0.001), 58.9% (p = 0.0027) and 61.8% (p = 0.0062), respectively; despite the fact that the concentration of the PBLs was lower in MDS patients respect to the controls (Supplementary Table 3, http://links.lww.com/HS/A61). Abnormal dendritic cell-poiesis in patients with lower-risk myelodysplastic syndromes. HemaSphere, 2020;4:1. http://dx.doi.org/10.1097/HS9.00000000000335
respect to control pDCs (0%–25%). MDS cDC2s were also mainly negative for CD85k (0%–17%) and 5%–25% of MDS cDC2s were CD85K positive (Fig. 1C). These data indicate that, in lower-risk MDS, pDCs and DC2s display a tolerogenic status, which is clearly diminished in control DCs. Almost all control cDC1s (75%–100%) and 65%–100% of control cDC2s were positive for CD80, while lower-risk MDS cDC1s and cDC2s presented a decreased expression of CD80 (Fig. 1C). Besides, the CD80 mean fluorescence intensity (MFI) was higher in control CD80⁺cDC1s and CD80⁺cDC2s compared to their MDS cell counterparts (cDC1s: control 7484 ± 1054, MDS 4122 ± 811 p = 0.03; cDC2s: control 3140 ± 391, MDS cDC2s 1772 ± 637 p = 0.004). pDCs are not as good antigen-presenting cells as cDCs (Supplementary Table 1, http://links.lww.com/HS/A61). Consistently, both control and MDS pDCs display a lower expression of CD80, with low MFI values, when compared to cDCs. These data indicate that the in vivo cDCs antigen-presentation to T cells could be impaired in lower-risk MDS. Almost all control cDC1s and cDC2s were positive for CD54 and its expression decreased in a significant manner in both lower-risk MDS cDC1s and cDC2s. Besides, the MFI was again significantly higher in control cells (cDC1s: control 5707 ± 390, MDS 3774 ± 235 p = 0.001;

**Figure 1.** Lower-risk MDS circulating cDC1s, pDCs, and cDC2s are reduced and abnormal. (A) Gating strategy to identify circulating cDC1s, pDCs, and cDC2s. Single live circulating leukocytes were plotted for HLA-DR vs lineage (Lin) (CD3, CD19, CD20, and CD56) and CD34. HLA-DR⁺Lin⁻CD34⁻ cells were then gated on CD141 and CD370. Then, CD141⁺CD370⁻ cells were identified as cDC1s. CD141⁻CD370⁻ cells were further plotted according to their CD123 and CD303 expression. CD123⁺CD303⁻ cells were identified as pDCs. CD123⁻CD303⁻ cells were subdivided based on their HLA-DR and CD1c expression, and HLA-DR⁺CD1c⁺ cells were identified as cDC2s. (B) Charts showing the amount of peripheral blood cDC1s, pDCs, and cDC2s as indicated in control (Cnt) and lower-risk myelodysplastic syndromes (MDS) (n = 32 and 19, respectively). (C) Percentage of positive cDC1s, pDCs, and cDC2s for CD85K, CD54, CD80, CD83, and CD86 markers of control (Cnt, light gray) and lower-risk MDS patients (MDS, dark gray) in peripheral blood; (n = 12 and 8, respectively). (B, C) Two-tailed Student t test was used for comparisons between groups. Mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001.
Figure 2. CDPs increase with respect to their precursors, GMDPs and MDPs, in bone marrow of lower-risk MDS patients. (A) Representative flow cytometry plots (left) and dots chart (right) displaying the percentage of CD10+ cells within CD34+CD38− cell population in BM of control (Cnt) and lower-risk MDS patients (MDS). (B) Representative plots showing the percentage of CD45RA− (CMPs and MEPs) and CD45RA+ (GMDPs, MDPs, and CDPs) cell populations within CD10−CD34+CD38− cells. (C) Percentage of CMPs plus MEPs (left hand panel) and GMDPs together with MDPs and CDPs (right), within CD34+CD38− cells, from samples described in A. (D) Left, representative graphs showing the percentage of GMDPs, MDPs, and CDPs within Lin−CD45RA+CD10−CD34+CD38− cells in BM of control and lower-risk MDS patients. Right, percentage of CDPs within CD45RA−CD10−CD34−CD38− cells in BM from samples described in A. (F) Model of DC-poiesis in control and lower-risk MDS patients. The number of cells depicted symbolize the relative proportion of the indicated cell populations in human lower-risk MDS and control bone marrow and peripheral blood. CDPs is the only cell population that is not reduced comparing lower-risk MDS and controls. DC, dendritic cell; GMDPs, granulocyte monocyte dendritic cell progenitors; MDPs, monocyte dendritic progenitors; CDPs, common dendritic cell progenitors. (A-E) Mean ± SEM; n = 10 in both groups. Two-tailed Student t tests were used for comparisons between 2 groups, *p < 0.05, **p < 0.01, ***p < 0.001.
cDC2s: control 4028 ± 3291, MDS 2649 ± 637, p = 0.043). The percentage of CD34 expression in control and lower-risk MDS tended to be similar, but the MFI was 1.8-fold higher in control pDCs (control 5018 ± 364, MDS pDCs 2835 ± 274, p = 0.002) (Fig. 1C). These data imply that another quality of DCs, their adhesion capacity, could be impaired in vivo in lower-risk MDS patients.

Both monocytes and DCs are closely related in the hematopoietic hierarchy, as they share the same lineage-restricted monocyte dendritic progenitors (MDPs). Monocytes under certain conditions are able differentiate into mono-DCs. Other groups have shown that the in vitro generation of both mono-DCs from MDS circulating monocytes and DCs from MDS bone marrow (BM) CD34+ cells is impaired in MDS.9,10 Moreover, MDS mono-DCs, and MDS DCs generated in vitro from MDS patients show a poor endocytic capacity, impaired cytokine production and a deficient induction of T-cells proliferation.6,9,11

These in vitro data agree with our findings, which suggest an altered acting capacity in vivo of circulating DCs in lower-risk MDS patients, besides the previously described reduction of the three circulating DCs.

To better understand the origin of this DC reduction in lower-risk MDS blood, we analyzed the DC lineage-restricted cell progenitors encompassed within the BM CD34+CD38+ cell compartment by flow cytometry (10 patients and 10 controls, Supplementary Fig. 1, http://links.lww.com/HS/A61). In lower-risk MDS patients peripheral blood DCs are the circulating myeloid cells that show a greater reduction (Supplementary Table 2, http://links.lww.com/HS/A61). Each dendritic cell type analyzed here plays a specialized immune and in plastic syndromes.1,2

In lower-risk MDS patients peripheral blood DCs are the circulating myeloid cells that display an increased susceptibility to infections, an inadequate DC-poiesis, and a deficient number of abnormal circulating DCs.

Acknowledgments

The authors thank Laura Molero and Inés Amich for their cytometry and experimental assistance and Rebeca Perez de Diego for the critical reading of the manuscript. We also want to thank Hospital Clínico San Carlos Biobank.

References

1. Ganan-Gomez I, Wei Y, Starczynowski DT, et al. Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes. Leukemia. 2015;29:1456–1468.

2. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–2465.

3. Villani AC, Satija R, Reynolds G, et al. Single-cell rna-seq reveals new dendritic cell subsets in t cell programming: location dictates function. Nat Rev Immunol. 2017;356eaaah4573.

4. Eisenbarth SC. Dendritic cell subsets in t cell programming: location dictates function. Nat Rev Immunol. 2017;356eaaah4573.

5. Ma L, Delforge M, van Duppen V, et al. Circulating myeloid and lymphoid precursor dendritic cells are cionally involved in myelodysplastic syndromes. Leukemia. 2004;18:1451–1456.

6. Schmidt SV, Nico-Castro AC, Schultz JL. Regulatory dendritic cells: there is more than just immune activation. Front Immunol. 2012;3:274.

7. Littringer K, Moresi C, Rakebrandt N, et al. Common features of regulatory t cell specialization during th1 responses. Front Immunol. 2018;9:1344.
9. Matteo Rigolin G, Howard J, Buggins A, et al. Phenotypic and functional characteristics of monocyte-derived dendritic cells from patients with myelodysplastic syndromes. Br J Haematol. 1999;107:844–850.

10. Micheva I, Thanopoulou E, Michalopoulou S, et al. Impaired generation of bone marrow cd34-derived dendritic cells with low peripheral blood subsets in patients with myelodysplastic syndrome. Br J Haematol. 2004;128:808–814.

11. Davison GM, Novitzky N, Abdulla R. Monocyte derived dendritic cells have reduced expression of co-stimulatory molecules but are able to stimulate autologous t-cells in patients with mds. Hematol Oncol Stem Cell Ther. 2013;6:49–57.

12. Buenrostro JD, Corces MR, Lareau CA, et al. Integrated single-cell analysis maps the continuous regulatory landscape of human hematopoietic differentiation. Cell. 2018;173:1535–1548.

13. Will B, Zhou L, Vogler TO, et al. Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations. Blood. 2012;120:2076–2086.

14. Pang WW, Pluvainage JV, Price EA, et al. Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes. Proc Natl Acad Sci U S A. 2013;110:3011–3016.

15. van Leeuwen-Kerkhoff N, Lundberg K, Westers TM, et al. Human bone marrow-derived myeloid dendritic cells show an immature transcriptional and functional profile compared to their peripheral blood counterparts and separate from slan+ non-classical monocytes. Front Immunol. 2018;9:1619.

16. Titmarsh GJ, McMullin MF, McShane CM, et al. Community-acquired infections and their association with myeloid malignancies. Cancer Epidemiol. 2014;38:56–61.